Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 6/20 | 0.76 |
| ▸ | KDR | P35968 | 3/20 | 0.66 |
| ▸ | CFTR | P13569 | 9/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29171356 | 0.86 | BAZ2B (0.82) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL12868564 | 0.82 | LMNA (0.78) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL30228575 | 0.81 | BAZ2B (0.74) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL21162488 | 0.81 | BAZ2B (0.74) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL23828254 | 0.79 | CFTR (0.75) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL3087738 | 0.79 | BAZ2B (0.70) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL23828253 | 0.77 | CFTR (1.00) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL23828290 | 0.77 | CFTR (1.00) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL30570539 | 0.77 | CFTR (1.00) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL168545 | 0.77 | ALOX15 (0.97) | BAZ2BKDRCFTRUSP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273208-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NORTHWESTERN UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170152228-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NORTHWESTERN UNIVERSITY (US) | 2017-06-01 | — | — | US | disclosed |
| US-9586890-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NORTHWESTERN UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160016893-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152228-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NEDD4, STUB1, CUL1 | BAZ2B 1189/4885KDR 2512/4885CFTR 3784/4885 |
| US-20160016893-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NEDD4, STUB1, UBQLN1 | BAZ2B 379/4885KDR 1693/4885CFTR 3826/4885 |
| US-10273208-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NEDD4, STUB1, CUL1 | BAZ2B 1189/4885KDR 2512/4885CFTR 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.